A Multi-center, Open-label, Randomized, Controlled Phase I Trial to Investigate the Effects of Cilengitide (EMD 121974) Using Dynamic MR and FET-PET Imaging as a Pharmacodynamic Measure of Response in Subjects With Newly Diagnosed Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2013
At a glance
- Drugs Cilengitide (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Pharmacodynamics
- 01 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 26 Mar 2012 New trial record